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1. Introduction
1.1. Islet cell transplantation for type 1 diabetes
The transplantation of pancreatic islets of Langerhans is a promising treatment for “brittle”
type 1 diabetics, because it is a minimally invasive procedure that replenishes the beta cell
mass lost due to autoimmunity. This procedure also provides an opportunity for a “cure”
from diabetes based on the achievement of freedom from dependence on exogenous insulin
and severe hypoglycemic events. Although islet transplants had been attempted for several
decades, they achieved minimum success in terms of post-transplant graft function. The
publication of the Edmonton Protocol [1] documenting consistent achievement of insulin in‐
dependence after islet transplantation, has led to a dramatic increase not only in the number
of procedures performed worldwide but also in other related areas in the field of islet trans‐
plantation. Breakthroughs have been made in the area of pancreas procurement and preser‐
vation with study into ductal preservation, the two layer method, and the type of
preservation solution used. Furthermore, there has been much progress in the islet isolation
process by bringing standards up to cGMP qualifications, optimization of collagenase en‐
zymes, and using iodixanol for continuous density gradient purification [2]. Some of the
hurdles facing further success in this treatment are:
i. lack of suitable donor pancreases;
ii. difficulties in isolating high quality islets on a consistent basis;
iii. improving the engraftment of transplanted islets;
iv. development of an islet-friendly immunosuppression and
v. improving long-term survival of transplanted islets.
© 2013 Takita et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1.2. Post-transplant outcome
According to a recent report from the Collaborative Islet Transplant Registry, 677 patients
have received either an islet transplant alone (ITA) or islets-after-kidney (IAK) transplants
[3]. There has been a remarkable improvement in the post-transplant graft function in recent
times. Prior to the publication of Edmonton protocol, the achievement of insulin-independ‐
ent status by islet transplant recipients was <10%. Patients treated initially under the Ed‐
monton protocol showed remarkable achievement of 82% insulin-independent status at one
year post-transplant. However, this result proved to be unsustainable when the five year in‐
sulin-independence rates fell to 12.5% at the same center [4]. This data resulted in skepticism
on the use of allogeneic islet transplantation as a reliable treatment for long-term success.
With the introduction of thymoglobulin at induction phase and the combination of prograf,
rapamycin and/or mycophenolate mofetil as maintenance immunosuppressive agents, the
islet transplant survival rate has significantly improved to 50% at five year post-transplant
[5]. Control of inflammatory reaction during peri-transplant period with the use of TNF-α
blockers also played a key role in this improvement. These remarkable results necessitated
comparison with whole pancreas transplantation which is considered as an established clini‐
cal procedure. Although whole organ treatment achieved high levels of graft survival in the
years 1994-1997, the islet survival rate at five years has reached around fifty percent in
2010-2011, comparable to the level of whole pancreas graft success [5]. Moreover, islet cell
transplantation seems to confer significantly better glycemic control than maximal medical
therapy, and essentially eliminates hypoglycemic unawareness. These results have brought
back the enthusiasm in this field.
2. Molecular mechanism of beta cell dysfunction
2.1. Early events after islet transplantation
The liver is the most commonly used site for transplantation of islets. Data supporting the
use of this transplant site came from autologous islet transplants in patients with chronic
pancreatitis, which showed that islets can function inside the liver for several years. There
are several drawbacks associated with the liver as a host site for islets. Major factors affect‐
ing islet function include hypoxia, drug toxicity and instant blood-mediated inflammatory
reaction (IBMIR). Together, these events may lead to loss of up to 75% of islet transplant
mass. IBMIR is primarily a response of innate immune system to isolated islets. Major char‐
acteristics of IBMIR include activation of coagulation and complement cascades and infiltra‐
tion of inflammatory cells. Several approaches are adopted to minimize the deleterious
effects of IBMIR which include infusion of low molecular weight dextran sulfate and also
inclusion of anti-inflammatory molecules during the infusion of islets. Besides the innate im‐
mune response, islets transplanted into liver may experience low oxygen tension. Activation
of resident Kupffer cells may pose additional risk to islet survival. In addition, high concen‐
trations of immunosuppressive drugs in the portal vein are likely to exert toxic effect on the
transplanted islet mass [6].
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2.2. Alloimmunity
The exposure of body to allogeneic tissues via organ/cell transplantation, blood transfusions,
pregnancy can cause development of anti-human leukocyte antigen (HLA) antibodies [7].
These de novo HLA antibodies have been shown to play a significant role in the early graft
loss after solid organ transplantation [8]. Currently, HLA matching between the recipients
and donors is not performed before islet cell transplantation. Moreover, to achieve and/or
maintain insulin independence and good metabolic control in an islet recipient, multiple is‐
let infusions from multiple donors and high doses of immunosuppressants are generally re‐
quired. The requirement of multi-donor infusions and reduction or weaning of
immunosuppressants due to significant adverse effects could cause patients eventually to
develop HLA antibodies against islet graft.
The issue of sensitization of alloantigens after islet cell transplantation has been raised by the
Edmonton group in 2007 [9]. 98 islet transplant recipients were screened for HLA antibodies
by flow-based methods. Twenty-nine patients (31%) represented de novo donor specific anti‐
bodies following islet transplantation. Among 14 recipients who discontinued immunosup‐
pression, 10 recipients (71%) were largely sensitized with panel reactive antibody ≥50%. On
the other hand, only 11 of 69 (16%) recipients who continued immunosuppression became
broadly sensitized posttransplant. This study suggested that development of HLA antibod‐
ies after islet transplantation is concerning and withdrawal of immunosuppression complete‐
ly following failed islet transplantation raises the risk for broad sensitization. Along with the
report of Edmonton group, there are several studies that have demonstrated that islet alone
transplant recipients develop donor-specific and/or nondonor-specific HLA antibodies, espe‐
cially following discontinuation of immunosuppression [10-13].
In contrast, in the report of Geneva group it was shown that multiple islet infusions did not
act as a risk factor for appearance of anti-HLA antibodies [14]. The group claimed that trans‐
plantation of islets in liver might cause less immunogenicity. After combined kidney-islet
transplantation and continued immunosuppression even with failed islet graft function, pa‐
tients had a low risk for sensitization as long as their kidney remained functional.
It has been known that islets express mainly HLA class I antigens on their surfaces. Previous
reports demonstrated that patients develop antibodies posttransplant not only against HLA
class I antigens, but also against HLA class II antigens [9]. Jackson et al. showed that there
would be an induction of HLA class II expression on human islets under inflammatory con‐
ditions, which in return may be a possible cause of allosensitization [15]. For this aim, the
group conducted an experiment in which they had two groups of isolated human islets;
group 1 was control group and cultured at 37˚C, whereas group 2 was cultured in the same
condition and treated with tumor necrosis factor alpha (TNF-α) and interferon gamma (INF-
γ). Presence of HLA class II on islet surface was analyzed by real-time polymerase chain re‐
action (PCR), immunofluorescence and flow cytometry. Expression of class II transactivator,
HLA-DR-α and HLA-DR-β1 increased maximum 9.38, 18.95 and 46.5 fold respectively in
group 2 compared to control group after 24 hours of incubation with TNF-α and INF-γ
which is shown by real-time PCR analysis. Fluorescent imaging and flow cytometric analy‐
sis confirmed the significant increase in the expression of HLA class II expression both on
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islet α and β cells after cytokine treatment. Inflammatory conditions shortly after islet trans‐
plantation up-regulates HLA class II antigens on islet surfaces that trigger alloimmunity.
Thus, protocols which provide adequate and efficient control of inflammation after islet
transplantation should be considered to improve islet transplant outcome.
Collaborative Islet Transplant Registry reported the sensitization rates against HLA class I
antigens pre- and posttransplant in islet alone recipients in 2011 [16]. Data is collected from
303 islet alone recipients between January 1999 and December 2008. Panel reactive antibody
(PRA) pretransplant and PRA at 6 months and yearly posttransplant correlated to measures
of islet graft failure. Pretransplant PRA showed not to be a predictor of islet graft failure;
whereas there was 3.6 fold increased hazard ratio for graft failure when the recipient devel‐
oped PRA ≥20% post-transplant. Each additional islet infusion increased the cumulative number
of mismatched HLA alleles from a median of 3 to 9; respectively for one infusion and for 3
infusions. Significantly higher rate of PRA ≥ 20% was observed in recipients who had com‐
plete graft loss with discontinued immunosuppression compared to recipients who had func‐
tioning grafts with continuing immunosuppression. Development of de novo  HLA class I
antibodies is less pronounced in recipients with exposure to repeat HLA class I mismatched
than increased class I mismatch. Reducing the number of islet donors used for each patient
and repeating HLA I mismatches with consequent islet transplantation without presence of
donor specific anti-HLA antibodies are vital factors to decrease the risk of allosensitization.
Currently, there is no clearly defined monitoring tool for alloimmunity in islet cell trans‐
plantation, but researchers have proposed many experimental tools to assess alloreactivity
in islet transplanted patients. Alloantibodies, soluble CD30 level, cytotoxic lymphocyte gene
expression and microparticles in peripheral blood are the markers which were shown to de‐
tect allogeneic rejection after islet transplantation. Monitoring panel reactive antibody in im‐
munosuppressed recipients had little clinical value to assess islet graft survival [16, 17].
Team Approach Outcome References
Edmonton group Alloantibodies Pretransplant HLA antibodies reduce graft survival
after islet transplantation.
[9]
CITR report  Alloantibodies Monitoring PRA in immunosuppressed patients
had little clinical value for islet graft survival.
[16]
Minnesota group Soluble CD30 No correlation between sCD30 levels and graft
function at 1 year was found.
A greater reduction in sCD30 levels posttransplant
was associated with full graft function.
[18]
Miami group  Cytotoxic lymphocyte (CL)
 gene expression
Increased CL gene levels could predict islet
allograft loss.
[19]
GRAGIL group  Microparticles MPs and C-peptide showed opposite pattern.
MPs levels in peripheral blood increase with acute
rejection of islet allograft.
[20]
Table 1. Immunologic tools to assess alloimmunity after islet cell transplantation
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Soluble CD30 (sCD30) is a cell membrane protein of tumor necrosis factor receptor family.
sCD30 is released into blood with the activation of CD30 + T cells, leading to speculation
that it may act as a marker for immune system activation [21]. Although it has been shown
to be predictive for acute rejection in lung, kidney, and heart transplantation [22-24], there
are not many reports about the role of sCD30 in the prediction of early graft loss following
islet transplantation. In the study of Hire et al., 19 allograft islet recipients treated with three
different immunosuppression inductions were evaluated retrospectively for the serum
sCD30 levels [18]. Pretransplant, early posttransplant day (day 4−7), one month posttrans‐
plant, late posttransplant (day 90−120) sCD30 levels were measured and correlated with islet
graft outcomes at 1 year. No correlation between sCD30 levels at any time point and graft
function at 1 year was found. However, a greater reduction in SCD30 levels posttransplant
was associated with full graft function. Therefore, sCD30 may be of value for immune moni‐
toring of islet allografts.
Cytotoxic lymphocyte (CL) genes granzyme, Fas ligand and perforin may play an active role
in the course of acute allograft rejection. University of Miami group studied 13 islet trans‐
plant recipients treated with steroid-free immunosuppressive regimen in order to demon‐
strate whether CL gene expression could be a predictor of allogeneic rejection [19]. All
patients attained insulin independence; however, 8 of them restarted insulin therapy. Real-
time PCR was used to assess CL gene mRNA levels. The group demonstrated that recipients
who restarted insulin therapy had a significant elevation of CL gene mRNA levels and the
most reliable measure of ongoing graft loss was granzyme B. Hence, increased blood CL
gene levels might be a potential marker to predict islet allograft loss.
Microparticles (MP) are plasma membrane fragments of apoptotic cells in peripheral blood.
The quantity of microparticles is correlated with the degree of cell death, so they are consid‐
ered to be indicators of apoptosis. Kessler et al. demonstrated the elevation of microparticles
in peripheral blood at the time of acute rejection following intraportal islet transplantation
with a case report [25]. Loss of islet graft function without the presence of GAD65, IA2 or
anti-HLA antibodies brought up the diagnosis of acute cellular rejection. With a successful
steroid bolus therapy, MPs level declined and the patient regained islet function. In 2011,
Toti et al. [20] demonstrated from three islet transplant recipients that in the case of rejec‐
tion, C-peptide and MPs levels exhibited opposite pattern and a decline in C-peptide was
related with increased insulin needs. This data suggested an increment in MPs level might
indicate allogeneic rejection. Thus, MPs level in peripheral blood might be a useful tool to
monitor allogeneic rejection after islet transplantation.
2.3. Autoimmune recurrence
Type 1 diabetes is an autoimmune disease in which pancreatic beta cells are destroyed
through a T-cell mediated mechanism in genetically susceptible individuals [26]. Autoanti‐
bodies against pancreatic islets comprise anti-glutamate decarboxylase 65 (GAD65), islet cell
autoantibody (ICA), anti-insulin autoantibody (IAA), anti-tyrosine phosphatase autoanti‐
body (IA-2) and against zinc transporter ZnT8. Antibodies present in serum against these
pancreatic islet antigens are commonly used to predict and or diagnose the disease in clini‐
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cal practice. For successful islet cell replacement, it is crucial to prevent recurrent destruction
of beta cells through existing autoimmune destruction. The graft failure due to recurrent au‐
toimmunity in a pancreas segment transplanted between identical twins was proven with
the demonstration of insulitis in the transplanted tissue [27]. Islet specific T cells seem to
have a basic role in the process of autoimmune destruction of beta cells [28].
To investigate T-cell allo- and autoreactivities in peripheral blood following islet transplan‐
tation, Roep et al. examined 7 islet allograft recipients [29]. They showed that three patients
who got thymoglobulin for induction immunosuppression and retained full islet function
for more than 1 year exhibited minor autoreactivites but no alloreactivities. Three patients
who did not get thymoglobulin had rapid decline (<3 weeks) in islet function and showed
alloreactivities; but one out of these three patients had rapid increase in autoreactivity to
several islet autoantigens prior to alloreactivity. One recipient who did not receive thymo‐
globulin exhibited hyperautoreacivity with no detectable alloreaactivity and developed de‐
layed loss of islet graft function consequently (<33 weeks); which indicated that
autoimmune recurrence might be the cause of chronic islet graft dysfunction. In this study,
because of the excellent outcomes in thymoglobulin group, the authors evaluated allo- and
autoimmunity again in a bigger sample sized group in 2008 [30]. 21 islet recipients under
thymoglobulin induction and tacrolimus plus mycophenolate mofetil maintenance immuno‐
suppressive regimen were studied. Immunity against allo- and autoantigens were checked
at pretransplant and at 1 year posttransplant. The analyses showed that existence of cellular
autoimmunity pretransplant and posttransplant was related with delayed insulin independ‐
ence and lower levels of circulating C-peptide during the first year posttransplant. Seven out
of eight patients with no previous T-cell autoreactivity achieved insulin independence;
whereas none of the four patients with autoantibodies against GAD and IA-2 before trans‐
plantation became insulin independent. Cellular alloreactivity and autoantibody levels did
not show significant involvement with the outcome. Based on these findings, the authors
commented that thymoglobulin may cope sufficiently with alloimmunity, but insufficient to
control islet autoreactivity in an early period. The issue of autoimmunity remains unad‐
dressed and needs further investigation.
Team Approach Outcome References
Roep et al. Autoantibodies Autoandibodies increased due to autoimmune
activity, but did not indicate loss of graft function.
[29]
Roep et al. T-cell autoreactivity
in peripheral blood
Pre- and posttransplant cellular autoimmunity
were associated with delayed insulin
independence.
Autoantibody levels did not affect islet allograft
outcome.
[30]
Matsumoto et al. GAD65 specific global
immune assay
Broad repertoire of islet antigen-specific T cells
secreting various cytokines were related with
chronic graft failure.
[31]
Table 2. Immunologic tools to assess autoimmunity after islet cell transplantation
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Autoimmunity recurrence might be assessed by monitoring islet specific autoantibodies and
T-cell autoreactivity. But the association between autoantibodies and insulin independence
and islet graft outcome are variable; increase in autoantibody levels were shown due to au‐
toimmune activity but did not indicate loss of islet graft function [29, 32]. Assays that meas‐
ure anti-islet cellular autoimmunity before and after islet transplantation demonstrated that
pre-and posttransplant cellular autoimmunity were related with delayed insulin independ‐
ence and lower levels of circulating C-peptide during the first year posttransplant [30].
Nonetheless, in this study islet allograft outcome did not seem to be affected by autoanti‐
body levels or cellular alloreactivity.
Matsumoto et al. have reported on a global immune assay specific for GAD65 (EpiMax) in
order to analyze the property of autoreactive T-cell responses [31]. Five type 1 diabetic pa‐
tients were studied 1 year after allogeneic islet transplantation. All patients achieved insulin
independence at 1 year. Three out of five patients maintained long-term insulin independ‐
ence and EpiMax affirmed minimum T-cell responses in these patients. In contrast, the two
patients who developed chronic graft failure and lost insulin independence showed broad
repertoire of GAD65 specific T-cells secreting various types of cytokines, including IL-5,
IL-13, IL-17, TNF- alpha, and IFN-gamma. In addition to those observations, IFN-γ and
IL-13 expressing CD4+ T cells and IFN-γ expressing CD8+ T cells were encountered in the
other two failed patients. These findings suggested that broad repertoire of islet antigen-
specific T cells which secrete variable types of cytokines were related with chronic graft fail‐
ure, preventing islet recipients from maintaining long-term insulin independence.
Immunosuppression
Following transplantation of islets, administration of immunosuppression is essential to
maintain graft function. However, most of the immunosuppressive drugs also have adverse
effects on beta cell function. Careful selection of immunosuppressive regimen is critical for
prolonged function of transplanted islets.
2.3.1. Early period of islet cell transplantation
Corticosteroid was a widely used agent as maintenance immunosuppression in the pioneer‐
ing days of islet cell transplantation in 1990’s (Table 3). During this decade, majority of islet
cell transplants were after or performed simultaneously with kidney transplantation. Corti‐
costeroid has antiinflammatory as well as immunosuppressive effects by direct or indirect
actions on various leukocytes, including T lymphocytes, monocytes and macrophages,
through glucocorticoid receptor [33, 34]. However, steroid therapy leads to β cell dysfunc‐
tion and insulin resistance. [35, 36] Deterioration of insulin secretion from β cell by steroid
treatment has been reported, caused by enhanced α-adrenergic receptor signaling [37], β cell
apoptosis [38] and activated K+ channel [39]. Insulin resistance in liver, adipose tissue and
skeletal muscle by long-term steroid administration are well known clinically and in basic
studies [40-42]. Thus, steroid use for the purpose of maintenance immunosuppression has
been averted in the recent decade of islet transplantation (Table 3).
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The calcineurin inhibitors (CNIs) have been major players in maintenance immunosuppres‐
sion of islet cell transplantation. Cyclosporine A and tacrolimus are currently available CNIs
in clinic. They inhibit calcineurin, a serine-threonine phosphatase, which is responsible for
dephosphorylation of nuclear factor for activated T cells (NF-AT), which in turn results in
inactivation of the transcription of cytokine genes. However, CNIs might have β cell toxicity
since calcineurin is expressed in β cell and regulates β cell growth as well as function [43, 44].
Azathioprine is a purine analog, serving as a blocker of de novo pathway in purine synthe‐
sis in actively proliferative cells such as T cells and B cells [45]. Currently this drug is used for
immunosuppression in allogeneic transplantation and autoimmune disease like rheumatoid
arthritis as well as therapy in hematologic malignancies [46]. Azathioprine may also prevent
the onset of diabetes [47, 48] and no major β cell toxicity of azathioprine has been reported.
2.3.2. Edmonton protocol
Remarkable success in islet transplant survival was achieved by the University of Alberta
group using steroid-free immunosuppression regimen that included daclizumab, tacrolimus
and sirolimus, resulting in that all 7 recipients achieving insulin independence [1]. The bene‐
fit of Edmonton protocol is to eliminate the risk of steroid-induced β cell toxicity as well as
insulin resistance and increasing the dose of transplanted islets. However, the protocol uses
tacrolimus that has the effect of β cell deterioration.
Publi-
cation
year
Pts
no.
Induction
therapy Maintenance therapy
Transplant
type
Donor
no.*
Major
outcomes Refs
Steroid CNIs Other
1990 9 ✓Tac Islet after livertransplant M/S
5 pts
achieved II [49]
1991 3 ✓Pred ✓CsA ✓Aza ITA M/S
Rejected 2
weeks after
ITA
[50]
3 ✓mALG ✓Pred ✓CsA ✓Aza IAK S Partialfunction**
3 ✓mALG ✓Pred ✓CsA ✓Aza IAK M II for 7, 14and 121 days
1991 4 ✓ATG(3 pts) ✓Pred ✓CsA ✓Aza IAK M/S
1 pt achieved
II [51]
2 ✓ATG ✓Pred ✓CsA ✓Aza SIK M/S
1992 10 ✓Tac
Simultaneous
Islet-Liver
transplant
S 6 ptsachieved II [52]
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Publi-
cation
year
Pts
no.
Induction
therapy Maintenance therapy
Transplant
type
Donor
no.*
Major
outcomes Refs
4 ✓Pred ✓Tac
Simultaneous
Islet-Liver
transplant
S Partialfunction**
7 ✓Pred ✓Tac SIK M Partialfunction**
1993 2 ✓mALG
✓15-DSG ✓Pred ✓CsA ✓Aza SIK S
1 pt achieved
II [53]
1997 6 ✓mPred ✓Tac
Simultaneous
Islet-Liver-Bone
marrow
transplant
S 3 ptsachieved II [54]
1997 8 ✓OKT3 ✓mPred ✓CsA ✓Aza IAK (7 pts)or SIK (1 pt) M/S
2 pts
achieved II [55]
1997 20 ✓ATG ✓Pred ✓CsA ✓Aza IAK (7 pts)or SIK (13 pt) M/S
7 pts
achieved II [56]
1997 3 ✓ATG ✓Pred ✓CsA ✓MMF SIK (2 pts)or IAK (1 pt) M/S
Partial
function** [57]
1998 7 ✓ATG (3pts) ✓Pred ✓CsA ✓Aza IAK M 2 ptsachieved II [58]
1999 12 ✓ATG ✓Pred ✓CsA ✓Aza IAK (12 pts)or SIK (12pts) M/S
Partial
function** [59]
Table 3. Immunosuppression protocols in clinical islet transplants published in 1990’s. *M: Multiple donor transplants,
S: Single donor transplant. ** Not achieved II, but positive C-peptide or decreased insulin requirement was confirmed.
Abbreviations; 15-DSG: 15-deoxyspergualin, ATG: antithymocyte globulin, Aza: azathioprine, CNIs: Calcineurin
inhibitors, CsA: Cyclosporine A, IAK: Islet after kidney transplantation, II: Insulin Independence, ITA: Islet
transplantation alone, mALG: Minnesota antilymphoblast globulin, MMF: mycophenolic mofetil, mPred:
methylprednisolone, Pred: Prednisone, SIK: Simultaneous islet kidney transplantation, Tac: Tacrolimus.
Publi-
cation
year
Pts
no.
Induction
therapy Maintenance therapy
Transplant
type
Donor
no.*
Major
outcomes Refs
Steroid CNIs Other
2000 13 ✓ATG or
✓Bas ✓Pred ✓CsA
✓Aza or
✓MMF
SIK, IAK or Islet
after lung
transplant
M/S 2 pts achievedII [60]
2000 7 ✓Dac ✓Tac ✓Sir ITA M 100% II [1]
2001 2 ✓ATG or
✓Bas ✓Pred ✓CsA ✓MMF
SIK (5 pts) or
IAK (2 pts) M/S
Partial
function** [61]
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Publi-
cation
year
Pts
no.
Induction
therapy Maintenance therapy
Transplant
type
Donor
no.*
Major
outcomes Refs
2001 10 ✓Bas ✓Pred ✓CsA ✓MMF IAK M/S 2 pts achievedII [62]
2003 6 ✓Dac ✓Tac ✓Sir ITA M/S 3 pts achievedII [63]
2004 6 ✓OKT3γ1 ✓Tac ✓Sir ITA S 4 pts achievedII [64]
2004 13 ✓Dac ✓Tac ✓Sir ITA (9 pts) orIAK (4 pts) M
11 pts
achieved II [65]
2004 10 ✓Dac ✓Tac ✓Sir ITA M/S 5 pts achievedII [66]
2004 6 ✓Dac ✓Tac ✓Sir SIK M 5 pts achievedII [67]
2005 8
✓ATG
✓Dac
✓Eta
✓Tac ✓MMF
✓Sir ITA S
100% II after
single infusion [68]
2005 16
✓Dac
✓Inf
(8pts)
✓Tac ✓Sir ITA M/S 14 ptsachieved II [69]
2005 22 ✓Dac/
✓Bas
✓Tac/
✓CsA
✓Sir/
✓Eve IAK or ITA M/S
15 pts
achieved II [70]
2005 65 ✓Dac ✓Tac ✓Sir ITA M/S 44 ptsachieved II [4]
2005 10 ✓ATG or
✓Bas ✓Tac
✓Sir or
✓MMF ITA M/S 100% II [71]
2006 8 ✓Dac ✓Tac ✓Sir IAK M/S 100% II [72]
2006 6 ✓Dac ✓Tac ✓Sir ITA M 3 pts achievedII [73]
2006 36 ✓Dac ✓Tac ✓Sir ITA M/S 16 ptsachieved II [74]
2007 11 ✓Dac ✓Tac
✓Sir or
✓MMF
plus
✓Exe
M/S 8 pts achievedII [75]
2007 10 ✓Dac ✓Tac ✓Sir ITA M/S 6 pts achievedII [76]
2007 19 ✓Dac ✓Tac ✓Sir or
✓MMF ITA M/S
16 pts
achieved II [77]
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Publi-
cation
year
Pts
no.
Induction
therapy Maintenance therapy
Transplant
type
Donor
no.*
Major
outcomes Refs
2008 5 ✓ATG ✓Tac ✓Sir ITA M 3 pts achievedII [78]
5 ✓ATG ✓Sir ITA M Partialfunction**
2008 13 ✓Dac ✓Tac ✓Sir SIK M/S 7 pts achievedII [79]
2008 7
✓Dac
✓Inf
✓Eta
✓ Pred (2
pts) or
mPred (1
pt)
✓Tac
✓Sir
✓MMF
(2 pts)
IAK M/S 6 pts achievedII [80]
2008 6 ✓ATG
✓Eta ✓CyA
✓Eve
→MMF ITA M/S
5 pts achieved
II [81]
2008 4 ✓Dac ✓Tac ✓Sir ITA M 100% II [82]
6 ✓Dac
✓Eta ✓Tac
✓Sir
✓Exe ITA M/S 100% II
2008 3 ✓Ale ✓Tac ✓Sir
✓MPA ITA M/S
2 pts achieved
II [83]
2008 6 ✓Dac
✓Inf ✓Tac ✓Sir
Islet transplant
with Bone
marrow
S 3 pts achievedII [84]
2009 14 ✓Dac ✓Tac ✓Sir ITA M 100% II [85]
2009 15 ✓Dac or
✓Bas ✓Tac ✓Sir IAK M/S
100 pts
achieved II [86]
2010 8 ✓ATG
✓Sir
✓MMF
✓Efa
ITA M/S 100% II [87]
2010 8 ✓Dac ✓Tac ✓Sir ITA M/S 100% II [88]
4 ✓Dac ✓Tac ✓Sir
✓Efa ITA S
100% II after
single infusion
2010 5 ✓ATG
✓Bela
✓Sir or
✓MMF ITA M/S
100% II after
single infusion [89]
5 ✓ATG
✓Efa
✓Sir or
✓MMF ITA M/S
100% II after
single infusion
2011 3
✓ATG
✓Eta
✓Ana
✓Tac ✓MMF ITA M/S 100% II aftersingle infusion [90]
3 ✓Dac ✓Tac ✓Sir ITA M 100% II
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Publi-
cation
year
Pts
no.
Induction
therapy Maintenance therapy
Transplant
type
Donor
no.*
Major
outcomes Refs
2011 4 ITA** M/S Partialfunction*** [91]
Table 4. Immunosuppression protocols in clinical islet transplants published after 2000. *M: Multiple donor
transplants, S: Single donor transplant. **Microencapsulated islets transplanted. *** Not achieved II, but positive C-
peptide or decreased insulin requirement was confirmed. Abbreviations; Ale: Alemtuzumab, ATG: antithymocyte
globulin, Aza: azathioprine, Ana: anakinra, Bas: basiliximab, Bela: belatacept, CNIs: Calcineurin inhibitors, CsA:
Cyclosporine A, Dac: daclizumab, Efa: efalizumab, Eta: etanercept, Eve: everolimus, Exe: exenatide, IAK: islet after
kidney transplantation, II: insulin independence, Inf: infliximab, ITA: islet transplantation alone, mALG: Minnesota
antilymphoblast globulin, MMF: mycophenolic mofetil, MPA: mycophenolic acid, mPred: methylprednisolone, Pred:
prednisone, SIK: simultaneous islet kidney transplantation, Sir: sirolimus, Tac: tacrolimus
Sirolimus is an inhibitor of mammalian target of rapamycin (mTOR), which plays an impor‐
tant role in cell cycle from late G1 to S phase in T cells [92]. The effect of sirolimus in β cell
function is still unclear; impaired β cell proliferation and islet graft function by sirolimus has
been reported [93-95] while Melzi et al found no significant adverse effect of sirolimus in is‐
let engraftment [96]. Gao et al reported sirolimus and daclizumab did not show any individ‐
ual or synergistic negative effects on islet proliferation [97]. However, insulin independence
in Edmonton protocol was not sustained for a long-term resulting in 12.5% at 5 year after
islet transplant [4].
2.3.3. Newer immunosuppression protocols
Recent clinical trials implementing monoclonal antibodies such as basiliximab (anti-IL-2 re‐
ceptor)[70], efalizumab (anti-LFA-1)[89], alemtuzumab (anti-CD52)[83] have shown high rate
of insulin independence after transplant. These monoclonal antibodies are produced as mo‐
lecular targeting agents and considered as less likely to have direct effects on β cell function.
Currently major islet transplant centers are increasingly adopting stronger induction immu‐
nosuppression comprised of T cell depletion using anti-thymocyte globulin, alemtuzumab
or OKT3γ1 (anti-CD3) plus anti-TNF-α treatment. This has resulted in significantly im‐
proved long-term maintenance of insulin independence [3, 5].
In maintenance immunosuppression, tacrolimus is still a key medication; although, there is
controversy on the use of tacrolimus and its effect to islet graft function as described above
(See § 2.5.1). Mycophenolate mofetil (MMF) is also used for maintenance immunosuppres‐
sion, inhibiting proliferation of T and B cells and promoting apoptosis of activated T cells
[98, 99]. Gallo et al recently showed that MMF was able to reduce survival of β cells, impair
glucose-stimulated insulin secretion and β cell proliferation [100]. Posselt et al reported ex‐
cellent islet transplant outcome using CNI-free immunosuppression that included belata‐
cept [89], which is a fusion protein with Fc fragment of a human IgG linked to cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4) that allows costimulation blockade of CD80 and
CD86 on antigen presenting cells [101]. Overall islet investigators have continued to make
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efforts to find effective immunosuppression with less effect on β cell function while enhanc‐
ing β cell function such as exenatide which is a glucagon-like peptide-1 (GLP-1) analog [75].
2.4. Islet encapsulation
The islet encapsulation aims to eliminate or reduce the dose of immunosuppression, which
is a major obstacle in current islet transplantation, by isolating islets from blood flow and
avoiding direct interaction with antibodies and immune cells such as lymphocytes and mac‐
rophages. However, few clinical trials using encapsulation technique have been reported
[91, 102]. The University of Peruga group demonstrated the efficacy of microencapsulated
human islets with sodium alginate in 4 type 1 diabetic patients, who were able to reduce
HbA1c level and the amounts of exogenous insulin injection [91]. Elliot RB et al. showed a
case report on xenotransplantation using alginate-encapsulated porcine islets, also allowing
reduction of insulin dose [102]. In both reports, islet recipients did not use any immunosup‐
pressants although insulin independence was not achieved, suggesting the advantage and
limitation of current encapsulation strategy (Figure 1).
There are several methods of islet encapsulation; macrocapsular devices, microencapsula‐
tion and surface modification. A macrocapsular device that is composed of polytetrafluoro‐
ethylene membrane enabled delayed onset of diabetes in mice model [103]. Microencapsulation
of islets has been prepared using various materials such as alginate, agarose and collagen
[104-106]. An issue of microencapsulation is the enlargement of the size of islet mass; micro‐
encapsulation of an islet can increase the size by as much as 3 to 5 folds of the original islet.
Alternatively, surface modification of islets is a strategy to reduce the tissue volume. Polyethy‐
lene glycol (PEG) is a hydrogen polymer and can be used for conformal coating to encapsu‐
late islets in the process of polymerization [107]. PEGylation, i.e. PEG conjugation at the islet
surface, is the another way of islet encapsulation without significant increase in tissue size
[108]. Recently, PEGylation attached with biologically active agents of heparin, activated protein
C, urokinase or thrombomodulin has been developed to prevent the local coagulation imme‐
diately after islet infusion [109-112]. These techniques were recently developed and the sus‐
tainability of PEGylation needs to be proven.
Figure 1. Benefits and current limitations of islet encapsulation.
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3. Clinical assessment of beta cell function
Monitoring graft function is a major concern in clinical management of islet recipients since
islet graft dysfunction in both acute phase after transplant and chronic phase is an obstacle
to its widespread use as a standard care for type 1 diabetes. Furthermore, isolated islets are
transplanted via the portal vein into the liver, making it difficult to employ biopsy examina‐
tion of engrafted islets. Hence, several methodologies to predict islet graft function indirect‐
ly have been proposed. In this section, indices currently available for clinical assessment of
islet graft function are discussed (Table 5).
3.1. Blood tests and clinical indices
3.1.1. Glucose tolerance/stimulation test
Glucose tolerance test (GTT) is a basic assessment method to diagnose diabetes although
glucose stimulation; in itself has risk of artificial hyperglycemia for type 1 diabetic patients.
Baidal et al reported that acute insulin/C-peptide release, mixed meal stimulation index,
time-to-peak C-peptide, 90min glucose level and area under the curve of glucose values
could predict islet dysfunction [113]. Arginine stimulation test is also useful for the evalua‐
tion of islet graft function. Glucose-potentiation slope and the maximal response in arginine
stimulation test were significantly associated with β cell secretory capacity in a report from
University of Pennsylvania group [114].
3.1.2. HYPO score and LI
Hypoglycemic (HYPO) score and lability index (LI) are calculated based on patients’ jour‐
nals of self-monitoring blood glucose (SMBG) for a month, providing a link to graft function
through the quality of glycemic control [115]. These assessment tools are beneficial since a
major endpoint of clinical allogeneic islet transplantation is to prevent hypoglycemic events;
however, HYPO and LI calculations require a number of glucose measurements and hence
are only calculated on a monthly or yearly basis using a complex scoring system.
3.1.3. SUITO index
A simple evaluation method using fasting blood glucose and C-peptide levels has been pro‐
posed, called secretory unit of islet transplant objects (SUITO) index [116]. The SUITO index
was originally developed using the concept of the homeostasis model assessment for insulin
secretion (HOMA-β) model, where healthy person has 100 of SUITO index. The calculation
uses serum C-peptide levels instead of insulin levels, since islet recipient may be administer‐
ing exogenous insulin during graft dysfunction and overlapped measurement of endoge‐
nous and exogenous insulin amounts are avoided [117]. SUITO index can provide reference
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value for insulin independence and elimination of hypoglycemia [118]. In addition, SUITO
index allows extensive link to quality of life in islet recipients [119].
3.1.4. C-peptide/glucose ratio and C-peptide/glucose*creatinine ratio
C-peptide per glucose ratio (CP/G) is also a simple technique to predict islet graft function
using blood glucose and C-peptide, similar to the SUITO index [120]. To correct islet graft
function in patients with renal dysfunction, C-peptide/glucose*creatinine ratio has also been
proposed. University of Miami group showed that CP/G correlated with 90min glucose level
and β score [120].
3.1.5. β score
This scoring system uses data on fasting blood glucose, HbA1c, stimulated C-peptide, and
absence of insulin or oral diabetic medication, that cover multiple aspect of glycemic control
in islet recipients [121]. Correlation between β score and 90 min glucose level after mixed
meal tolerance test has also been reported.
3.1.6. TEF
Transplant estimated function (TEF) is calculated by a formula using daily exogenous insu‐
lin requirements and HbA1c, that are routinely measured at clinic, eliminating glucose stim‐
ulation test when compared to β score [122]. TEF correlated well with β score and insulin
response to arginine stimulation test.
3.1.7. TFIM model
Transplanted functional islet mass (TFIM) model is a recently proposed index that is aimed
to guide the decision to use a specific islet preparation [123]. TFIM model is composed of
transplanted islet volume, increment of insulin secretion, cold ischemia time and exocrine
tissue volume transplanted, and can predict islet graft function.
3.2. Clinical image study
Functional mass of transplanted islets can be observed by the combination of the radioiso‐
tope-labeled grafts using 18F-fluorodeoxyglucose ([18F]FDG) and positron emission tomog‐
raphy with computed tomography (PET/CT) [124, 125]. Although this technique is only
applicable to capture early phase of transplantation up to 60 min after transplant, islet graft
loss as well as transplanted islet distribution in the liver can be observed. Nano-iron particle
also visualizes engrafted islet mass using magnetic resonance imaging (MRI) and allows
longer follow-up when compared to PET/CT technique [126, 127].
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Method Variables required Advantage Disadvantage Reference
GTT A series of glucose or C-
peptide values during
glucose stimulation
Widely available method in
clinic
The risk of hyperglycemia
Repeated blood collection
[113, 114]
HYPO score
and LI
Detailed self-recorded
journal of glucose levels
and hypoglycemic episodes
Direct evaluation of
hypoglycemia that is a
major outcome in islet
transplantation
Number of records for
monthly basis are required
Complex calculation for LI
[115]
SUITO index Fasting serum C-peptide
and glucose level
Simple calculation
Easy prediction of graft
function corresponding to
insulin independence.
Limited application to
other species
[118, 119]
CP/G Fasting serum C-peptide
and glucose level
Simple calculation Limited information on
extended outcomes of
hypoglycemia
[120]
β score Fasting glucose, HbA1c,
Daily insulin dose,
Stimulated C-peptide
To capture multiple aspects
of glycemic control
Composite scoring system
requiring 4 variables
including the results from
glucose stimulation test
[121]
TEF A series of records on
HbA1c and daily insulin
amounts
To eliminate glucose
stimulation test compared
to β score
Calculation using variables
that can be collected in
standard diabetes care
Adjustment of coefficients
by individual patient
[122, 128]
TFIM Model Volume of transplanted
islets, increment of insulin
secretion, cold ischemia
time and volume of
transplanted exocrine
tissue
To follow graft function
using isolation results
Validated using data on
islet after kidney
transplantation
[123]
Radiologic
imaging
technique;
PET/CT
Radioisotope-labeled islets
PET/CT machine
To allow evaluation of islet
graft mass and the
distribution in the liver
The measurement only
applicable for early phase
of transplantation due to
half-time of radioisotope
Labeling procedure
required
[124, 125]
Radiologic
imaging
technique;
MRI
Iron-nanoparticle labeled
islets
MRI machine
To allow longitudinal follow
up of islet mass
Labeling procedure
required
Iron overload
[126, 127]
Table 5. Clinical assessment of β cell function
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3.3. Autologous Islet Transplantation
Patients with refractory chronic pancreatitis undergo total or partial pancreatectomy to alle‐
viate pain and also autologous islet transplantation to retain pancreatic endocrine function
after surgery. Islets isolated from pancreas are infused intraportally into the liver. Assess‐
ment of beta cell function in such autologous islet transplant patients typically follows the
methods described for allogeneic islet transplantation. For example, the SUITO index can be
applicable to autologous islet transplantation and was founded as an excellent predictor of
insulin independence [129]. However, no immune response against infused islets is expect‐
ed in these patients. Post-transplant function of autologous islets has been shown to be
much better than in allogeneic combination; β cell mass more than 10,000 IEQ/kg of islet
yield is considered for a factor of insulin independence in allogeneic transplants while islet
yield over 5,000 IEQ/kg is the successful factor in autologous transplantation [130]. After
achievement of insulin independent status, patients receiving autologous islets have better
long term survival of graft. Most patients also achieve significant relief from pain and im‐
prove their quality of life.
4. Conclusion
Islet transplantation has been shown to be a very promising treatment that could result in
freedom from requirement of exogenous insulin in type 1 diabetic patients. One of the major
advantages of islet transplantation is the minimally invasive nature of the procedure when
compared to whole organ pancreas transplantation. Despite its wide spread use at several
major transplant centers, the volume of patients receiving islet transplants remain low when
compared to the number of “brittle” type 1 diabetic patients eligible for this procedure. Re‐
cently impressive gains have been made in the improvement of post-transplant islet func‐
tion. This is primarily due to the use of T-cell depleting immunosuppression during
induction phase after transplant followed by use of tacrolimus, rapamycin and or mycophe‐
nolic mofetil during the maintenance phase. In addition several advances made in donor se‐
lection, pancreas procurement, enzymatic digestion, islet purification and islet culture seem
to have contributed to this success. Recent completion of a large scale phase III clinical trial
sponsored by the NIH has given hope that soon this procedure may be approved for clinical
use. In light of these advances, there is optimism that the remaining hurdles could be over‐
come to improve the long term function of the transplanted islets.
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